November 15, 2004
SpeculatingStocks.com Stock Pick: Matrixx Initiatives, Inc. (MTXX)
Stock Price: $13.85 (short-term strong buy)
We first released MTXX as a stock pick on August 9th at $8.42 as a long-term strong buy. MTXX has since ran up over 75% and has become a major cough/cold play. The chart is almost identical to last year and we believe MTXX will hit $20 by the end of the year.
Matrixx Initiatives, Inc. is the developer and distributor of the expanding line of Zicam products created by their wholly-owned subsidiary Zicam, LLC. Zicam cold products reduce the duration and severity of the common cold. Other products within the brand include sinus and allergy relief.
The company has higher overall net sales this year and could exceed its 52-week high of $20.89 in the near future. They reported strong third quarter numbers including net sales up 26% and net income up 33% over the same period last year. Zicam, their major product is beginning to generate major sales, and should continue to gain traction through retail outlets such as Walmart.
MTXX fell $0.86 on Friday; however, this just created a buying opportunity for investors.
SpeculatingStocks.com Target Price: We expect MTXX to rise above $20 by the end of the year.